Revvity, Inc. (RVTY) Financial Statements
Historical financial data — 12 statements covering FY2023–FY2025
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and in...
Revvity, Inc.'s revenue increased 3.7% year over year, from $2.76B to $2.86B.
Net income decreased 10.8% over the same period, from $270.4M to $241.2M.
Total debt decreased by 16.5% to $2.63B.
The debt-to-equity ratio stands at 0.36, indicating a moderate leverage profile.
Operating cash flow declined 7.2% to $582.9M.
Revvity, Inc. maintains a moderate net profit margin of 8.4%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2023 | $2.05B+48.5% | $614.5M | $1.16B | $223.4M | $-105.3M | $13.42B | $3.15B | $7.69B |
| Q1 FY2024 | $649.9M-68.4% | $26.0M | $355.0M | $44.1M | $147.6M | $13.43B | $3.16B | $7.85B |
| Q2 FY2024 | $1.34B+106.4% | $81.4M | $740.6M | $129.8M | $306.2M | $13.42B | $3.16B | $7.87B |
| Q3 FY2024 | $2.03B+51.0% | $175.7M | $1.13B | $228.0M | $454.1M | $12.77B | $3.19B | $7.92B |
| Q1 FY2025 | $664.8M-67.2% | $42.2M | $375.5M | $72.2M | $128.2M | $12.36B | $3.17B | $7.64B |
| Q2 FY2025 | $1.39B+108.4% | $96.2M | $768.1M | $163.0M | $262.5M | $12.36B | $3.21B | $7.56B |
| Q3 FY2025 | $2.08B+50.5% | $142.8M | $1.14B | $244.9M | $401.0M | $12.14B | $2.63B | $7.38B |
| Q1 FY2026 | $711.1M-65.9% | $40.7M | $387.7M | $75.9M | $115.2M | $12.00B | $2.63B | $7.18B |
Balance Sheet Summary (Latest Period)
Total Assets
$12.17B
Total Liabilities
$4.92B
Total Equity
$7.25B
Cash & Equivalents
$919.9M
Total Debt
$2.63B
Current Assets
$2.24B
Current Liabilities
$1.33B
Retained Earnings
$6.05B